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Background: Subjects with diabetes mellitus (DM) develop gait dysfunction contributing to falls, reluctance to
perform activities and injuries. Neuropathic pain (NeP) related to diabetic peripheral neuropathy (DPN) is associated
with increased gait variability that may contribute to gait dysfunction. We used a portable device (GaitMeter™) and
related gait and balance measures to measure gait parameters in painful DPN (PDPN) subjects prior to and during
analgesia. Our hypothesis was that PDPN subjects would have decreased gait step variability when receiving
pharmacological relief of NeP.
Methods: DPN subjects with at least moderate NeP were assessed in a randomized, double-blind crossover study
of pregabalin versus placebo. The outcome measure was variability in step length and step velocity. Testing for
Timed Get-Up-and-Go Test, Tinetti Mobility Scales, Sway Testing, a Physiological Profile Approach, and fall-related
surveys were also performed. DPN severity was quantified using the Utah Early Neuropathy Score.
Results: PDPN subjects developed increased, rather than decreased, step length and step velocity variability during
pregabalin treatment. There were no significant differences between cohorts for other physiological gait and
balance testing. Non-significant NeP relief occurred in the pregabalin phase of study as compared with placebo.
There was a negative relationship for step length with pain severity.
Conclusion: Analgesia did not decrease gait variability in PDPN patients, and in fact, increased gait variability was
seen during pregabalin treatment. Other important relationships of gait dysfunction with PDPN should be sought.
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A strong predictor for falling is the presence of dia-
betes mellitus (DM) [1,2]. Falling may occur in DM
patients due to its many systemic complications including
hypoglycaemia, orthostatic hypotension, obesity, car-
diovascular disease, vestibular dysfunction, visual impair-
ment, cognitive impairment [3], and age-related decline.
However, another important contributor may be diabetic
peripheral neuropathy (DPN), present in up to half of DM* Correspondence: corytoth@shaw.ca
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unless otherwise stated.causing sensory, motor and autonomic dysfunction [4]
impacting upon gait function [5].
Within DM subjects, those with DPN are more likely
to suffer falls [6]. Although possibly related to reduction
in proprioceptive input, other factors such as neuro-
pathic pain (NeP) related to DPN may play roles. NeP,
defined as pain initiated by a lesion or dysfunction of the
nervous system [7], is present in 25-50% of DPN patients
[8]. NeP in DPN (PDPN) leads to an “antalgic gait” [9],
assumed in order to circumvent or decrease pain while
walking. Antalgic gait is associated with reduced gait vel-
ocity, shorter cadence and step length, with less rhythmic
accelerations [10]. Although initially appearing to be a
more stable gait, an antalgic gait may actually have greateral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ability, defined as the extent to which gait parameters such
as step length or step velocity diverge from a mean value,
has been previously investigated by our group with refer-
ence to PDPN. We have previously hypothesized that gait
dysfunction, defined as abnormal or impaired functioning
of walking or running, may be associated with greater ex-
tents of gait variability [9]. Our previous work has demon-
strated that variability of step length and velocity increases
in PDPN subjects when compared to a cohort of painless
DPN subjects and control subjects [9], even though other
forms of chronic pain, such as with low back pain, can
contribute to reduced variability [12]. Thus, we postulated
that NeP, a potentially treatable risk factor, is contributory
to gait variability, gait dysfunction, and the subsequent
risk of falling.
We hypothesized that patients with PDPN would have
decreased gait variability with pharmacological NeP man-
agement using pregabalin, an indicated therapy for
PDPN. If pain due to PDPN is itself responsible for the
increased gait variability, then it could be theorized that
reduced pain severity would reduce such variability to
levels seen in DPN patients without pain. We per-
formed a randomized, double-blinded, cross-over study
comparing the effect of pregabalin, an effective pharma-
cotherapy for PDPN, compared with placebo interven-
tion. Gait variability was assessed using GaitMeter™, a
wireless, portable gait detection system previously stud-
ied in control subjects, DM patients, and patients with




This study was a single-center, double-blind, random-
ized, placebo-controlled cross-over clinical trial. Two
periods of six-week flexible-dose trials of pregabalin/
placebo were compared using the same subject as com-
parator, with two week washout phases intervening.
Ethical approval for this study was received from the
University of Calgary Centre for Advancement of Health.
Participant recruitment took place from August 2011-
January 2013 using poster recruitment at the tertiary
care clinics within the University of Calgary. Informed
written consent was received from all participants prior
to involvement. Each subject had pre-existing type 2 dia-
betes, based upon Canadian Diabetes Association guide-
lines. Further clinical and laboratory evaluation to verify
presence of DPN occurred. Age of DM diagnosis, dur-
ation of DPN, and use of anti-diabetes treatments and
other medications were documented. Any history of
other systemic illness, toxic and medication exposure,
alcohol use, and familial neuropathy was determined. All
recruited subjects performed laboratory testing at studyinitiation and completion to identify other peripheral
neuropathy causes [13]. Hemoglobin A1C, electrocardi-
ography and hepatic and renal function blood work were
performed at the beginning and end of each intervention
period.
Subject assessment
During baseline week, assessments and questionnaires
were completed. Daily pain severity and associated clin-
ical reporting diaries were initiated at baseline week, at
the end of first intervention, during the second week of
the washout phase, and at the end of second interven-
tion. During each of the six week intervention periods,
daily pain diaries were completed. Adverse events were
recorded during each visit.
A timeline for all visits is presented in Additional file 1:
Figure S1. At screening and final visits, a complete stan-
dardized neurological examination and full physical exam-
ination was carried out [13]. Each patient was scored
using the Utah Early Neuropathy Scale (UENS) determin-
ing DPN severity [14]. After clinical scales were com-
pleted, candidates were verified to have DPN if the UENS
score was ≥ 6. UENS scores of <6 led to exclusion due
to uncertainty regarding DPN presence. Verification for
PDPN presence was based upon the question “Do you
have pain on a daily or near daily basis?” If affirmative,
candidates then completed the Douleur Neuropathique
(DN) 4 questionnaire (DN4Q), categorizing pain as
NeP or non-NeP [15]. Candidates scoring ≥4 on the
DN4Q were categorized as PDPN, otherwise exclusion
occurred. Pain duration must have been ≥ 3 months with
pain severity at least 40/100 mm on the visual analog scale
(VAS) (Short-Form-McGill Pain Questionnaire) [16].
Allocation and criteria
A randomization table assigned subjects to the first
cross-over intervention phase. Randomization conceal-
ment occurred for subjects, the clinical coordinator,
and the study physician. Scheduled study portions were
as follows: 1) Pre-screening to allow wash-out of any
prohibited medications (see below); 2) a one week
screening period to ensure subject eligibility into the
study; 3) a six week randomized active treatment period
(Intervention 1); 4) a two week washout period with
weaning of pregabalin/placebo; 5) a six week random-
ized active treatment period (Intervention 2); and 6) a
one week follow-up period with weaning of placebo/
pregabalin (Figure 1). Telephone visits took place one
week into each intervention period, and one week after
the washout period to assess tolerability and adverse
effects.
Inclusion and exclusion criteria are provided in Table 1.
This was an adjuvant study - other pharmacotherapies
for pain relief excluding gabapentinoids were permitted
Figure 1 A flowchart of subjects throughout the study using the CONSORT guidelines.
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study. Prior use of pregabalin was permitted unless inef-
ficacy or intolerability arose after appropriate dosing.
Pharmacological interventions
For pregabalin interventions, subjects were commenced
on 75 mg po bid, with scheduled times to increase their
dose once weekly after initiation to 150 mg po bid and
then 300 mg po bid (maximum dose) if tolerated and
agreed upon. A decrease in dose was permitted on one
occasion to no less than 75 mg po bid. Tablets supplied
were of 75 mg size. Placebo tablets were identical in
appearance, size, color, taste, and smell and dosing.
Outcome measures
GaitMeter™ analysis was performed prior to and after
completion of 6 weeks for each pharmacological inter-
vention. As described [9], GaitMeter™ is a small, wire-
less, portable, inertia-sensing motion analysis system
using miniature accelerometers and gyroscopes attached
to the anterior mid shin regions permitting various
mobility tasks in a natural environment while data is
continuously stored on a personal handheld computer.
Subjects walked at normal pace for 50 metres using one
90 degree turn without rest time allowed. Data collectionoccurred between a few seconds before gait commence-
ment until a few seconds after conclusion. Step length was
measured individually for each leg and averaged in all
cases using tibial acceleration, as analyzed using Lab-
ViewDM (National Instruments, Austin, TX) software.
Although obtained, angular velocity measures were not
studied due to the linear nature of the task studied with
GaitMeter™. The first and last steps were not analyzed, as
these are not typically a full step and would contribute to
variability incorrectly if included. Step velocity was calcu-
lated using the distance and time of each individual leg’s
step as measured by GaitMeter™. The degree of statistical
variability in each of gait step distance and velocity was
used to calculate measures of gait variability, defined as
the extent to which the individual data diverged from the
average value using variance. Although GaitMeter™ has
been studied previously and found reliable, this device has
not been validated against an established device or pro-
cedure for evaluation of gait in this manner. Secondary
outcome measures included assessment of the mean dif-
ference in the average daily pain score, averaged from the
final seven entries in the daily pain diary during the last
week of the intervention period. Comparison was per-
formed with average scores obtained in either the baseline
week or in the last week of the washout period prior to
Table 1 Inclusion and exclusion criteria for study entry are listed
Inclusion criteria 1) Subjects aged ≥18 years
2) Females of childbearing potential must have a negative urine pregnancy test performed, and all subjects were required to be
practicing an effective form of contraception as required
3) A diagnosis of NeP due to DPN with NeP severity of ≥4 on a Visual Analog Score
4) Ability to complete pain diary and quality of life questionnaires and to perform GaitMeter™ and associated testing; and
5) The subject must be willing and able to comply with scheduled study procedures.
Exclusion criteria 1) Another co-existing pain for which the subject or a qualified pain physician cannot differentiate from NeP due to DPN
2) Clinically significant or unstable medical or psychological conditions
3) Any history of malignancy, except either where there has been no ongoing treatment for at least 6 months or for a basal cell
carcinoma
4) A history of seizures, clinically significant cardiac arrhythmias, postural hypotension, uncontrolled hypertension, severe
cardiovascular disease, severe hepatic impairment (evidence from medical history), renal failure or pulmonary disease
5) A history of another diagnosed disorder which could interfere with gait and testing, such as with stroke, dementia,
Parkinsonism, spinal cord disorder, muscle weakness, or use of a medication which causes significant sedation or incoordination
6) Hepatic dysfunction at screening (aspartate transaminase [AST] or alanine transaminase [ALT] greater than twice the upper limit
of normal, or a total bilirubin greater than the upper limit of normal
7) Estimated creatinine clearance of < 60 mL/min based on the Cockcroft and Gault equation
8) A positive urine drug screen
9) A lack of willingness to discontinue and wash-out use of prohibited medications or treatments
10) Inability to walk a total of 50 metres without any pauses or use of a cane, walker, or motorized device
11) Identification of the presence of another potential cause for peripheral neuropathy, presence of impaired glucose tolerance
only or juvenile onset of diabetes with requirement for insulin at time of diagnosis (i.e. possible type 1 diabetes)
12) Refusal to perform concurrent laboratory and physiological testing.
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using an 11-point numerical rating scale (NRS) from 0 =
no pain to 10 = worst possible pain using an average score
for the preceding 24 hours.
Secondary physiological outcome measures were per-
formed at baseline week, at the last week of the washout
period, and at the end of each intervention period. A
Physiological Profile Approach (PPA) [17] was performed
- this tests high and low contrast visual acuity, visual field
dependence, peripheral sensation (tactile, vibratory, and
proprioceptive sensation), muscle force using dynamome-
try, reaction time, and balance using standard clinical
measures and complimentary measures. Corrected visual
acuity testing was performed using a standardized Snellen
eye chart. Proprioceptive testing was performed at the
knee as described [17], with scoring in degrees of disparity
between levels of the great toes. Contrast sensitivity was
performed using the Vistech chart to determine orienta-
tion of gratings provided in rows of circles differing in con-
trast [18], scored as logarithmic values of inverses. Blood
pressure measurements for lying, sitting, and standing
were performed using one minute latencies. Mobile hand-
held dynamometry using a Chatillon MSE100 dynamom-
eter (Digital Measurement Metrology, Brampton, ON) for
ankle dorsiflexion and plantar flexion [19] was performed.
Reaction times of the dominant foot using a visual stimu-
lus and recording of latency for the foot tapping on ameasurement device. Balance testing used four scenarios
to measure postural sway [17] – standing on floor with
eyes open or closed, and standing on 15 cm thick foam
with eyes open or closed, each for 30 seconds duration.
Sway was calculated using a rod fixed to the posterior as-
pect of a belt while on the opposite end, a computer tablet
pencil would scroll on touch-sensitive computer screen to
measure percentages of movement based upon the com-
puter screen area. Additional testing for determination of
fall risk included the Timed Get-Up-and-Go Test (TUG)
[20] and the Tinetti Assessment Tool (TAT) [21]. All sub-
jects also completed the Modified Falls Efficacy Scale
(MEFS) [22] and the Elderly Falls Screening Test (EFST)
[23] at 0, 2, 6 and 8 weeks into each intervention.
All adverse events, both spontaneously reported and
observed, were coded during each clinic or telephone
visit using Medical Dictionary for Regulatory Activities
(MedDRA) terminology. Vital signs and body weight
were measured at clinic visits. Electrocardiograms were
performed at screening and final visits.
Analysis
The primary endpoint was defined as a measurable dif-
ference in the absolute gait variability using GaitMeter
after 6 weeks of each intervention. Based upon the pri-
mary outcome measure, assuming a 2-sided alpha of
0.05 with a standard deviation of 0.02 (SD 0.02), a
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providing 90% power to avoid a type 1 error of <0.01 to
ensure reliability. We anticipated a 10% drop out rate,
and therefore 28 subjects were to be recruited.
The primary outcome measure analyzed was intra-
subject variability in gait for step length and velocity
considering all steps made by both limbs except for first
and last steps of the 50 metre walk. Intra-subject vari-
ability calculations averages were obtained for all sub-
jects during each intervention. Shapiro-Wilk testing was
performed to ensure normal distributions prior to com-
parisons of variance for variables of interest. If normality
was determined, then Bartlett-Box testing was performed
to assess for homogeneity of variance between cohorts,
using the null hypothesis that both interventions were as-
sociated with the same degree of variance for gait variables
of interest. In the case of non-normal distributions for
variance, general multivariate analysis of covariance
(MANCOVA) testing using intra-subject variability in
gait step length and step velocity as dependent mea-
sures with intervention was used as an independent
measure. MANCOVA testing can be used when there
are multiple dependent variables, yet significant differ-
ences between group means are sought. Each of the
above tests were previously used in our work prelimin-
ary to this study [9]. Interlimb differences for each
subject were compared for step length and velocity.
Post-hoc linear regression was performed for determin-
ing relationships of gait variability with measures of
step length, step velocity, and pain severity, using pain
severity as a dependent variable, and step velocity and
step length as independent or dependent variables
depending upon the assessment performed. Post-hoc
comparisons in the change in variability between base-
line and endpoint timepoints have also been performed
as a comparison between the two interventions admin-
istered. Absolute changes in variables were examined
for significant differences for all variables examined at
different time points. Separate ANOVA testing with calcu-
lation of F values was performed using Bonferroni correc-
tions for the remaining secondary and tertiary outcome
measures. α was set to be 0.05. Only data received from
patients completing the entire study was analyzed. Ana-
lysis occurred using Microsoft Excel 2007 (Office 2007,
Microsoft Corp, Washington State) or SPSS 14.0 (IBM,
Armonk, NY). An intention-to-treat analysis could not be
performed due to the primary outcome measure being
dependent upon the gait assessments occurring at both
the first and last week for each intervention.
Results
Participants
We recruited 28 subjects after assessing 33 potential
candidates (Figure 1). A total of 19 subjects completedthe entire study; discontinuations occurred in both inter-
vention periods due to inefficacy of pain relief and intol-
erability, with one patient lost to follow-up for uncertain
reasons (Table 2). There was no significant difference in
the numbers of other pain medications used between
baseline and endpoint times, or between the two inter-
ventions performed for either baseline and endpoint
timepoints.
Gaitmeter™ assessment revealed no significant differ-
ences in durations of time required to walk the entire 50
metres (Table 3) (ANOVA, p =NS, F = 0.3-0.7). Average
actual step length and step velocity measures were un-
changed between timepoints and interventions (ANOVAs,
p =NS, F = 0.5-0.9). The baseline degrees of both step
length and velocity variance varied between pregabalin
and placebo intervention periods, with the placebo inter-
vention demonstrating greater variability for both mea-
sures (Bartlett-Box tests, χ2 = 4.49-5.27, p = 0.022-0.034).
In contrast to our primary hypothesis, the degree of vari-
ability in both step length and step velocity significantly
increased for subjects receiving pregabalin for comparison
of baseline and final visits (Bartlett-Box tests, χ2 = 5.13-
9.27, p < 0.025). Although step length variability did not
change during the placebo intervention (Bartlett-Box
test, χ2 = 1.23,p = NS), step velocity variability decreased
during the placebo intervention (Bartlett-Box test, χ2 =
17.07, p < 0.001). None of the cohorts had greater vari-
ability with one leg as compared to the other leg (Bartlett-
Box tests, χ2 = 0.62-1.11, p = NS). Despite differences in
variability, there were no significant differences between
interventions with respect to step length or step velocity
(MANOVAs, p = NS, F = 0.7-1.0). However, there was a
difference in the change in variability from baseline to
endpoint measurements for each of step length variability
(Bartlett-Box test, χ2 = 6.22,p = 0.01) and step velocity vari-
ability (Bartlett-Box test, χ2 = 9.57, p = 0.001). Finally, there
were no significant differences for individuals between the
right and left legs for either of step length or step velocity
variability (ANOVAs, p = NS, F = 0.2-0.3).
Subjects during the pregabalin intervention period
received non-significant pain relief overall when com-
pared to placebo (Additional file 2: Figure S2). There
were no significant differences in pain scores at any
timepoint based upon either change from baseline or
for the cohort’s actual pain scores for each timepoint
(multiple ANOVAs, p = NS, F = 0.6 – 3.7). Scoring for
disruption of sleep due to pain had a similar non-
significant representation (Additional file 3: Figure S3).
Although the average score on the MEFS improved
initially with pregabalin intervention, overall scoring
representation was not significantly different between
interventions (Additional file 4: Figure S4).
There were no significant differences for each of high
and low contrast visual acuity, proprioceptive thresholds,
Table 2 Subject characteristics
All study subjects (n = 28) Subjects completing study (n = 19)
Age 64.6 ± 10.4 years 65.7 ± 10.8 years
Gender (males) 17/28 (61%) 16/19 (84%)
Duration of Diabetes Mellitus 7.2 ± 3.9 years 7.5 ± 4.1 years
Duration of Neuropathic Symptoms 5.7 ± 4.1 years 6.0 ± 4.3 years
Concomitant Diabetic
Complications Present (other than neuropathy) 5/28 (18%) 3/19 (16%)
Other Neuropathic Pain Medications Used 1.2 ± 1.1 1.4 ± 1.2
Weight (kg) 96.3 ± 26.8 94.6 ± 25.9
Height (cm) 170.9 ± 7.6 169.7 ± 7.8
Sitting Systolic Blood Pressure (mm Hg) 141 ± 18 139 ± 18
Sitting Heart Rate (/min) 72 ± 10 74 ± 12
Standing Systolic Blood Pressure (mm Hg) 140 ± 19 136 ± 20
Standing Heart Rate (/min) 73 ± 12 73 ± 13
Utah Early Neuropathy 16.3 ± 9.6 16.2 ± 6.5
Score
Douleur Neuropathique 4 Score 7.6 ± 1.0 6.9 ± 0.9
Block 1 Pregabalin Intervention Block 1 Placebo Intervention
Baseline Visual Analog Pain Score 6.1 ± 1.6 7.1 ± 1.3
Average Pregabalin 205.8 ± 28.9 188.1 ± 39.8
Dosage Achieved (mg)
Other Neuropathic Pain Medications Used 1.4 ± 1.2 1.4 ± 1.2
Values shown are means ± standard deviations.
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dorsiflexion and ankle plantar flexion) (Additional file 5:
Table S1) or with balance testing, reaction times, TUG
times, TAT scores, and EFST scores (Additional file 4:
Figure S4). There were no changes in corrected visual
acuity during the course of the study for any subject.
We used multiple linear regression analyses to identify
positive associations between step length and step velocity
(F = 12.5, R2 = 0.38, p < 0.0125), and for a negative rela-
tionship between step length and pain severity (F =
10.9, R2 = 0.33, p < 0.0125), but not for step velocity
and pain severity (F = 7.1, R2 = 0.24,p = NS).Table 3 Results of gait testing
Characteristic Pregabalin intervention -
baseline (n = 19)
Prega
final
Cadence (Steps/Minute) 137.0 ± 24.9 126.5
Duration of Time to Walk 50 Metres
(seconds)
39.8 ± 0.8 40.2 ±
Average Step Length (metres) 0.55 ± 0.11 0.59 ±
Average Step Duration (seconds) 0.44 ± 0.08 0.47 ±
Step Length Variance 0.060 ± 0.002 0.087
Step Velocity Variance 0.043 ± 0.001 0.066
Values shown are means ± standard deviations. MANOVA testing was used for step
measures shown. *p < 0.025 for comparison of baseline and final visit testing in the
testing for the pregabalin and placebo intervention periods. κp < 0.025 for comparisDiscussion
Not as hypothesized, subjects with PDPN receiving prega-
balin treatment had increasing variance for both step
length and step velocity. Surprisingly, subjects receiving
placebo had the unanticipated result of a decrease in step
velocity variance (but not for step length variance). These
differences occurred without other noted differences, and
we interpret these results as related to the interventions
themselves. Also, it is important to note that the clinical
importance of gait variability is unclear, and is not associ-
ated with any particular clinical and obvious outcome.
Our results suggest that management of pain relief maybalin intervention -
(n = 19)
Placebo intervention -
baseline (n = 19)
Placebo intervention –
final (n = 19)
± 24.2 137.4 ± 21.9 140.6 ± 22.9
1.1 39.7 ± 0.7 39.5 ± 0.9
0.13 0.55 ± 0.15 0.54 ± 0.15
0.09 0.44 ± 0.07 0.43 ± 0.07
± 0.010* 0.098 ± 0.005 0.100 ± 0.003
± 0.003* 0.058 ± 0.003Ψ 0.038 ± 0.000κ
length/velocity variance comparisons. ANOVA testing was used for other
pregabalin intervention period. Ψp < 0.025 for comparison of baseline visit
on of baseline and final visit testing in the placebo intervention period.
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the pregabalin intervention in our trial did not provide
significant pain relief limiting full interpretation of this
trial’s results.
The presence of PDPN contributed to greater gait
variability in our prior work [9], with potential contribu-
tion to postural instability and even falls. We hypothe-
sized that pain itself contributed to this variability and
development of an overly cautious antalgic gait with
smaller steps. However, the addition of pregabalin may
negatively impact gait function. Rats receiving extreme
pregabalin doses have a dose-dependent impairment in
rotarod performance [24]. Doses administered in our
study were about 1000 fold less by weight, but the sensi-
tivity of GaitMeter™ may be sufficient to identify small
changes in human gait. Rats receiving phenytoin or carba-
mazepine are subject to much more profound ataxia [24].
Although ataxia was not reported as an adverse effect, it
has been reported in addition to vertigo, nystagmus, inco-
ordination and balance disorders as due to pregabalin
[25], but with less magnitude than phenytoin and carba-
mazepine [26]. As such, it is possible that pregabalin’s
adverse effects may have contributed to our findings.
There was a non-significant improvement with pain
relief using pregabalin as a large confounder in this trial;
if greater pain relief had occurred, it is possible that
improved gait variability may have been observed. How-
ever, the discovery of placebo intervention’s association
with reduced gait variability was unanticipated. In stud-
ies examining gait parameters in patients with knee
osteoarthritis, placebo did not impact upon outcome
measures [27]. The degree of placebo response is highly
variable [28] and subject to particular personality types
[29]. Other studies, however, have identified placebo-
associated improvements in gait and balance [30]. Fur-
thermore, subjects with low back pain are subject to
reduced variability of gait [12], so perhaps the PDPN
population has other distinct features leading to gait
variability rather then the chronic pain itself.
Factors increasing gait dysfunction [31] include stride
time variability, poor functional status or physiological
capacity. Exercise programs may benefit instability [31].
Otherwise, management of gait dysfunction largely de-
pends upon the disease process. Management of Parkinson-
ism and cardiovascular conditions, for example, improves
gait dysfunction. Improvement in postural hypotension or
discontinuation of medications causing ataxia or sedation
can also improve gait. Fall prevention techniques are also of
value, including gait assistance devices.
DPN patients have other contributing factors for fall-
ing [6] beyond NeP. Proprioceptive and cutaneous
sensory loss also contributes. An antalgic gait in PDPN
patients also contributes to instability [11]. Antalgic
gait contributes to slow walking along with increasedstep frequency, reduced step length, less lateral sway
in center-of-mass, and reduced amounts of ankle plan-
tar flexion and hip extension movements, resulting in
greater gait variability [9]. However, treatment of PDPN-
associated NeP failed to reduce gait variability and, in fact,
increased gait variability. This suggests that NeP manage-
ment is unlikely to reduce risks of falling if of insignificant
amount, but it remains unclear if significant pain relief
may impact upon gait dysfunction.
Our findings should not dismay other research teams
from identification of other potential risk factors for
falling in DM. There are limitations to our results. The
largest limitation was the absence of successful pain
relief with pregabalin, either based upon change from
baseline pain severity or as an absolute difference. This
insufficient pain relief may have been due to a number
of possible factors including a type II error, insufficient
dosing, insufficient duration of treatment, or more re-
fractory pain in our patient population. Also, the design
of the study using both baseline and endpoint gait mea-
sures limited us from performance of an intention-to-
treat analysis. The presence of greater baseline gait
variability in the placebo intervention portions was un-
anticipated, and suggests that randomization may have
been better performed using a stratified approach after
baseline gait measures were performed. Calculation of
foot contact moments and other potentially useful mea-
sures could not be performed using GaitMeter™. We
did not formally assess cognitive function or vestibular
function. Our tertiary care patients enrolled may not be
representative of primary care populations. Although
sample size calculations were met, discontinutations
were more frequent than expected, dampening our re-
sults. Training effects over the four GaitMeter™ sessions
performed may have influenced the results of the sec-
ond intervention, and incomplete washouts may have
occurred. GaitMeter™ has been shown reliable in this
patient population based upon our prior work, but has
not received validation with comparison against estab-
lished gait analysis devices or procedures; as such, this
invalidation may have contributed to the unanticipated
results observed. Although other pain relief medica-
tions were stable, they may have impacted upon results.
There were large degrees of variance in many examined
measures, particularly with the baseline timepoint gait
measures in the placebo intervention group. Finally, the
lack of significant pain relief with pregabalin makes in-
terpretation of these results difficult.
Conclusion
Our results suggest that although PDPN impacts upon
gait stability [9], its potential relief using pharmacother-
apy may not improve gait dysfunction. Future studies
with larger sample sizes and other forms of management
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was not met, management of PDPN is clearly associated
with other significant benefits related to pain relief, im-
proved functionality and quality of life. We suggest that
further kinesiological assessments of patients with PDPN
are required to determine the reasons behind gait vari-
ability and its potential future management.
Additional files
Additional file 1: Figure S1. A timeline for all visits in this trial is
presented. In person visits are demonstrated by V1, V2, etc. while telephone
visits are not shown. During screening, informed consent is obtained.
History and physical examination, along with electrocardiography, blood
work, recording of number of falls, urine pregnancy testing and DN4
questionnaires are performed on visits marked with a plus sign (+). After the
run in phase and at the time of randomization to either of pregabalin or
placebo, gait and physiological assessments, along with performances of all
other questionnaires are performed for visits shown with an asterisk (*).
During the time of cross over to the other intervention, a 2 week washout
period occurs during weeks 7–8. The final visit occurs two weeks after the
completion of the second intervention (or with study dropout) as indicated.
Additional file 2: Figure S2. The impact of interventions upon VAS
pain severity levels. Over the time of the second intervention, the cohort
receiving placebo followed by pregabalin had significantly better pain
relief during the second intervention as compared to the cohort
receiving pregabalin, then placebo (informal post-hoc analysis, ANOVA,
p < 0.05) (A). However, when subjects are grouped according to intervention
received, there was a non-significant pain relief identified with the
pregabalin intervention (ANOVA, p = NS) (B). Values shown are means ±
standard error.
Additional file 3: Figure S3. The impact of interventions upon VAS
sleep disturbance severity levels. As with the pain severity measure, the
cohort receiving placebo followed by pregabalin had significant
improvement in sleep disturbance during the second intervention as
compared to the cohort receiving pregabalin followed by placebo
(informal post-hoc analysis, ANOVA, p < 0.05) (A). However, when
grouped based upon intervention received, there was a non-significant
impact upon sleep disturbance during the pregabalin intervention
(ANOVA, p = NS) (B). Values shown are means ± standard error.
Additional file 4: Figure S4. Scores on the Modified Efficacy Falls Score
were not significantly different between interventions (ANOVA, p = NS)
(A). Likewise, performance on balance testing did not change with either
intervention and was similar for all time points measured (multiple
ANOVAs, p = NS) (B). Reaction times were unchanged for any of the
studied timepoints also (ANOVA, p = NS) (C). Other assessments of
mobility, including the Tinetti Up and Go time (D), Tinnetti Assessment
Tool (E), and the Elderly Fall Screening Test score (F) were also
unchanged between interventions (multiple ANOVAs, p = NS).
Additional file 5: Table S1. Results of ancillary testing.
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